1. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?

   • Theocharis Koufakis
   • Omar G. Mustafa
   • Kalliopi Kotsa

   Current Opinion 07 July 2021 Pages: 1365 - 1371

   

2. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care

   • Stephan Jacob
   • Andrew J. Krentz
   • Lars Rydén

   Therapy in Practice 24 July 2021 Pages: 1373 - 1379

   

3. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations

   • Dimitrios A. Vrachatis
   • Konstantinos A. Papathanasiou
   • Spyridon G. Deftereos

   Review Article 23 July 2021 Pages: 1381 - 1395

   

4. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa

   • Pim Aarts
   • Koen Dudink
   • Hessel H. van der Zee

   Review Article Open access 20 July 2021 Pages: 1397 - 1410

   

5. Budesonide/Glycopyrronium/Formoterol: A Review in COPD

   • Young-A Heo

   Adis Drug Evaluation Open access 03 August 2021 Pages: 1411 - 1422

6. Pegcetacoplan: First Approval

   • Sheridan M. Hoy

   AdisInsight Report 03 August 2021 Pages: 1423 - 1430

   

7. Olanzapine/Samidorphan: First Approval

   • Julia Paik

   AdisInsight Report 24 July 2021 Pages: 1431 - 1436

   

8. Aducanumab: First Approval

   • Sohita Dhillon

   AdisInsight Report 29 July 2021 Pages: 1437 - 1443

   

9. Ibrexafungerp: First Approval

   • Arnold Lee

   AdisInsight Report 27 July 2021 Pages: 1445 - 1450

   

10. Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis

    • Tamara Pérez-Jeldres
    • Manuel Alvarez-Lobos
    • Jesús Rivera-Nieves

    Correction Open access 30 July 2021 Pages: 1451 - 1451